Drug Trial Radar · NCT01449162
Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids
Last checked: Nov 19, 2026Latest source record: Feb 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
420
Actual
Start
Jan 2011
Primary completion
Nov 2019
Study completion Nov 2019
Sponsor
- Lead sponsor
- AB ScienceIndustry
- Sponsor type
- Industry
- First posted
- Oct 10, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study objective is to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids.
Conditions
- Asthma
Interventions
MasitinibDrug
6 mg/kg/day
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Severe asthma exacerbation rateTime frame: Duration of patient treatment exposure, assessed until withdrawal from study, study completion date, or for a maximum of 60 months
Locations
8 sites in 6 countries. Site status is shown where the registry gives one.
Dr. Georgi Stranski University Hospital
Pleven, Bulgaria
Hospital Polyclinic Melnik
Mělník, Czechia
Hospital La Cavale Blanche
Brest, France
l'Hopital Albert Calmette
Lille, France
l'Hopital de la Croix Rousse
Lyon, France
University of Debrecen Medical and Health Science Center
Debrecen, Hungary
King George Hospital
Hyderabad, India
Hospital Universitario Doctor Peset
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.